Thanks to the latest research, we can now target specific migraine pathways.Brad C. Klein, MD, MBA
Abington Neurological Associates, Ltd. is pleased to offer new, cutting edge treatments for migraine. Often misunderstood, migraine is a neurological disorder involving nerve pathways and brain chemicals. It often runs in families, but it’s more than just genetics. Migraine will impact about 18% of all women and 6% of all men. Affecting 39 million Americans, it is more common than asthma and diabetes combined. While just about everyone gets tension headaches, most people don’t see their provider because these are generally easy to control. However, if a patient needs to see their doctor for their headaches, migraine is the most likely primary diagnosis.
Thanks to the latest research, we can now target specific migraine pathways, particularly those that cause inflammation in the brain and trigger symptoms such as pain, light and sound sensitivity, and nausea. One such chemical is called CGRP. This is a neuropeptide found in the brain and body. In the brain, it helps to transmit pain from one nerve to the next. By blocking this chemical, we can either prevent or stop migraine pain for many patients.
Vyepti is the first and only intravenous CGRP antagonist (IV anti-CGRP) that attaches to CGRP and blocks it from transmitting the pain. It is designed to deliver fast, powerful, and sustained migraine prevention. Not only can it help patients meet their migraine-free potential, they may achieve this with one 30-minute treatment every 3 months, working as fast as day 1. It is indicated for the preventive treatment of migraine in adults.
In over 2,000 patients, the only side effects occurring more than 2% of the time were a stuffy nose and scratchy throat, hypersensitivity, itching, or a flushing sensation on the day of dosing. Less than 2% of people receiving Vyepti stopped their treatments due to side effects.
For patients interested in helping bring a new migraine treatment to the public, ANA is also pleased to offer a clinical trial of an oral medication that may prevent migraine. This medication is a pill designed to block the CGRP pathway as well, but blocks the nerve receptor for CGRP. If a patient is interested in the trial, there is also no cost to the patient, nor does the patient require insurance.
For more information, please contact us at 215-957-9250.